Transgene Balance Sheet Health
Financial Health criteria checks 3/6
Transgene has a total shareholder equity of €15.6M and total debt of €16.0M, which brings its debt-to-equity ratio to 102.7%. Its total assets and total liabilities are €45.2M and €29.6M respectively.
Key information
102.7%
Debt to equity ratio
€16.04m
Debt
Interest coverage ratio | n/a |
Cash | €15.67m |
Equity | €15.61m |
Total liabilities | €29.61m |
Total assets | €45.22m |
Recent financial health updates
No updates
Recent updates
No updates
Financial Position Analysis
Short Term Liabilities: TNGP's short term assets (€18.0M) exceed its short term liabilities (€10.0M).
Long Term Liabilities: TNGP's short term assets (€18.0M) do not cover its long term liabilities (€19.6M).
Debt to Equity History and Analysis
Debt Level: TNGP's net debt to equity ratio (2.4%) is considered satisfactory.
Reducing Debt: TNGP's debt to equity ratio has reduced from 143.5% to 102.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TNGP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: TNGP has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.2% each year.